Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 4,499 matching trials from the live ClinicalTrials.gov search.
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
Intravenous Patient-Controlled Analgesia (IVPCA), Thoracic Epidural Analgesia (TEA), Questionnaires, Pain Assessment
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
28
States / cities
Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 24 more
Conditions
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Interventions
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Drug
Lead sponsor
Kineta Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more
Conditions
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, KRAS G12C
Interventions
FMC-376
Drug
Lead sponsor
Frontier Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 11 more
Conditions
Lung Cancer
Interventions
Mass Spectrometry
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
NSCLC, NSCLC, Stage I, NSCLC Stage II, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
Interventions
BIO 300
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
15
States / cities
Galesburg, Illinois • Elkhart, Indiana • Evansville, Indiana + 10 more
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
alrizomadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-small Cell Lung Cancer
Interventions
CyberKnife Stereotactic Radiosurgery
Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Fresno, California • Palo Alto, California + 18 more
Conditions
Lung Carcinoma
Interventions
Fluorescein, Image-Guided Needle Confocal Laser Endomicroscopy, Ultrasound-Guided Transbronchial Needle Aspiration
Other · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Lung Cancer
Interventions
becatecarin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Conditions
Non-small Cell Lung Cancer
Interventions
Docetaxel and cisplatin, Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lung Cancer, Driver Mutation
Interventions
Low Dose CT Scan
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
1,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Conditions
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Interventions
PF-07329640, sasanlimab, bevacizumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
Conditions
Non-small Cell Lung Cancer
Interventions
Ramucirumab, Necitumumab, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
Interventions
Bevacizumab, Carboplatin, Cetuximab, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
797
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
17
States / cities
Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Conditions
Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
Interventions
TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
Interventions
SEA-TGT, sasanlimab, brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more
Conditions
Advanced MTAP-null Solid Tumors
Interventions
Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Oxnard, California + 24 more
Conditions
Cancer, Non-Small Cell Lung Cancer
Interventions
XL765 (SAR245409), erlotinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions
cabozantinib
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Non Small Cell Lung Cancer
Interventions
[89Zr]Zr-DFO-emapalumab
Drug
Lead sponsor
Nerissa T. Viola
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas